rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PSNL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Did Wider Losses Just Shift Personalis (PSNL) Stock Investment Narrative?

      Personalis reported third quarter 2026 sales of US$25.6 million and a net loss of US$33.8 million, with basic loss per share from continuing operations of US$0.32. For the nine month period, the company reported sales of US$63.43 million and a net loss of US$95.52 million, or US$0.90 per share. The earnings update showed higher top line figures alongside wider losses, which highlights ongoing cost intensity and execution pressure as Personalis scales its cancer genomics business. We will...

      Nov 7Yahoo FinancePSNL
      Personalis earnings missed by $0.06, revenue topped estimates
      Nov 4Investing.comPSNL
      Personalis: Q3 Earnings Snapshot
      Nov 4Yahoo FinancePSNL
      Personalis Reports Third Quarter Results
      Nov 4Yahoo FinancePSNL
      The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings
      Oct 27Yahoo FinancePSNLTEM
      PSNL Investor Investigation: Personalis Shareholders Are Alerted to the Pending Investigation into the $16.25 per Share Merger
      Oct 27MorningstarPSNL
      Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026

      FREMONT, Calif., October 21, 2026--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. Highlights include a late-breaking oral presentation of NeXT Personal data for the C-POST Phase 3

      Oct 21Yahoo FinancePSNL
      Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test
      Oct 20Yahoo FinancePSNL
      Personalis (PSNL) Stock Looks Richly Valued As Shares Surge 14x In 3 Years
      Oct 20Yahoo FinancePSNL
      Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast (ARKK:BATS)

      Cathie Wood’s Ark Invest addedto its positions in AI infrastructure and social media companies, buying $25.9M of CoreWeave (CRWV) and $24.4M of Meta Platforms (META). It also purchased $16.3M of Cerebras Systems (CBRS) and $9.4M of Rocket Lab (RKLB)

      Oct 19Seeking AlphaCRWVPSNLTOST
      Why is Personalis stock sliding today?
      Oct 6Investing.comPSNL
      BTIG downgrades Personalis stock rating to neutral on acquisition outlook
      Oct 6Investing.comPSNL
      BTIG Downgrades Personalis to Neutral From Buy
      Oct 6Yahoo FinancePSNL
      Personalis: The Wrong Side Of The Merger (NASDAQ:PSNL)

      Personalis shareholders remain exposed to downside in TEM shares while having limited ability to benefit from further TEM appreciation above $48.42. Learn more about PSNL stock here.

      Sep 30Seeking AlphaPSNLTEM
      Personalis SVP, chief legal officer Stephen Moore sells $33,542 in shares
      Sep 27Investing.comPSNL
      Personalis CFO and COO Aaron Tachibana sells $47,540 in stock
      Sep 27Investing.comPSNL
      Personalis president & CMO Chen sells $64,847 of PSNL stock
      Sep 27Investing.comPSNL
      Personalis CEO Christopher Hall sells $120,984 in company stock
      Sep 27Investing.comPSNL
      The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
      Sep 4WSJMRNAPSNLTEM
      Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

      Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the […]

      Aug 27Yahoo FinanceMRNAPSNLTEM
      Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next.

      Personalis (PSNL) has demonstrated exceptional momentum, gaining nearly 250% over the past year. Shares recently set a new 3-year high. PSNL stock maintains a 100% “Buy” technical opinion from Barchart. Despite strong price appreciation, PSNL remains unprofitable and highly speculative, with mixed analyst sentiment and significant short interest. Today’s Featured...

      Aug 26Yahoo FinancePSNL
      Personalis falls amid a downgrade as a competitive bid appears unlikely
      Aug 24Seeking AlphaPSNLTEM
      Personalis Shares Fall After Craig-Hallum Downgrade
      Aug 24Yahoo FinancePSNL
      Tempus AI: Winning With Precision Medicine
      Aug 22Seeking AlphaPSNL
      Tempus AI Stock: Winning With Precision Medicine (NASDAQ:TEM)

      Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine. Learn why TEM stock is a strong buy.

      Aug 22Seeking AlphaPSNLTEM
      Tempus AI (TEM) Is Up 39.5% After mRNA Melanoma Trial Win And Personalis Deal - What's Changed

      In recent days, investors have reacted to phase 3 INTerpath-001 trial results showing a customized mRNA-based melanoma treatment improved recurrence-free survival, while also focusing on Tempus AI’s pending US$1.50 billion acquisition of Personalis Inc. as a move deeper into cancer genomics. Together, the trial success and acquisition plan highlight how Tempus AI is tying advanced mRNA oncology research to its broader precision medicine and data-driven cancer testing ambitions. We’ll now...

      Aug 22Yahoo FinancePSNLTEM

      This is the newest page. Registered accounts read further back.